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Dendritic cells (DC) are professional antigen presenting cells that have a key role
in shaping the immune response. Tolerogenic DC (tolDC) have immuno-regulatory
properties and they are a promising prospective therapy for multiple sclerosis and
other autoimmune diseases. Ethyl pyruvate (EP) is a redox analog of dimethyl fumarate
(Tecfidera), a drug for multiple sclerosis treatment. We have recently shown that EP
ameliorates experimental autoimmune encephalomyelitis, a multiple sclerosis murine
model. Here, we expanded our study to its tolerogenic effects on DC. Phenotypic analysis
has shown that DC obtained from mice or humans reduce expression of molecules
required for T cell activation such as CD86, CD83, and HLA-DR under the influence of EP,
while CD11c expression and viability of DC are not affected. Furthermore, EP-treated DC
restrain proliferation and modulate cytokine production of allogeneic lymphocytes. These
results demonstrate that EP has the ability to direct DC toward tolDC.
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INTRODUCTION
Tolerogenic dendritic cells (tolDC) are promising candidates for the cell-based immunotherapy
of autoimmune disorders, including multiple sclerosis (1). They are effective in restraining
antigen-specific and allogeneic T cell responses in vitro and their beneficial effects have been
demonstrated in the treatment of animal models of various autoimmune disorders (2). Moreover,
their administration to humans has been shown safe and efficient by increasing the proportion
of regulatory T cells in circulation (1). Vitamin D3 and dexamethasone are commonly used for
induction of tolDC (1, 2), while a number of agents has been shown effective for the induction of
tolerogenic properties over dendritic cells (DC). Ethyl pyruvate (EP) is a redox active compound
that has been shown potent as an anti-inflammatory agent (3). It is a safe and simple chemical
that has already been tested in humans (4). Importantly, it is a redox analog of dimethyl fumarate
(Tecfidera), a drug that is approved for multiple sclerosis treatment (5). Our group has recently
reported that EP ameliorates experimental autoimmune encephalomyelitis (EAE), an animal model
of multiple sclerosis (6). The major pathogenic T helper (Th) cells in the central nervous system
autoimmunity are interferon (IFN)-γ-producing Th1 cells and interleukin (IL)-17-producing Th17
cells (7). The beneficial effects of EP in EAE were paralleled with down-regulation of Th1/Th17
activity (6). Moreover, release/production of IL-6, tumor necrosis factor (TNF) and reactive
nitrogen and oxygen species by macrophages were also inhibited by EP. Noteworthy, IL-6 is known
to potentiate the resistance of effector T cells to regulatory T cells in multiple sclerosis (8), while
TNF actively contributes to demyelination and axonal degeneration in neuroinflammation (9).
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Correspondingly, reactive oxygen and nitrogen species
participate in the loss of oligodendrocytes, blood-brain barrier
dysfunction, T cell infiltration, and neurodegeneration (10).
Effects of EP were also observed within the CNS, where reactivity
of microglia and astrocytes was reduced (11).
We were also able to demonstrate that EP down-regulated the
expression of antigen presenting molecules on macrophages (6)
which led us to the investigation of the effects of EP on DC as the
major professional antigen-presenting cells. Here, we present that
EP exerts potent tolerogenic effect on murine and human DC. It
down-regulates the expression of antigen-presenting molecules
on DC, restricts the production of pro-inflammatory cytokines
in DC and diminishes their T cell-activating function.
MATERIALS AND METHODS
Monocyte-Derived Human DC
Buffy coats, provided by the Banc de Sang i Teixits (Barcelona,
Spain), were obtained from randomized healthy blood donors,
following the institutional Standard Operating Procedures
for blood donation and processing. Peripheral blood was
obtained from untreated relapsing-remitting multiple sclerosis
patients. The Ethical Committee of Germans Trias i Pujol
Hospital approved the study, and all subjects gave their
informed consent according to the Declaration of Helsinki
(BMJ 1991; 302: 1994). Peripheral Blood Mononuclear Cells
(PBMC) were isolated by Ficoll-Paque (Lymphoprep, Axis
Shield, Oslo, Norway) density gradient centrifugation at 400
× g for 30min. Recovered cells were washed twice in PBS
and counted using Perfect Count microspheres (Cytognos SL,
Salamanca, Spain) following the manufacturer’s instructions.
Establishing Monocyte-derived DCs, PBMCs were first depleted
of CD3+ T cells using the RosetteSepTM Human CD3 Depletion
Cocktail (StemCell Technologies, Seattle, WA, United States).
Afterwards, monocytes were obtained by positive selection using
the EasySep R© Human CD14 Positive Selection Kit (StemCell
Technologies). For all samples, the purity and viability of the
monocyte populations were >95 and 90%, respectively, as
assessed by the expression of specific markers and Annexin V
and 7-Amino-actinomycin D (7AAD) labeling (BD Biosciences).
Monocytes were cultured at 1 × 106/ml for 6 days in X-
VIVO 15 culture medium (BioWhittaker R©, Lonza, Belgium)
supplemented with 2% (vol/vol) heat inactivated AB human
serum (BioWhittaker R©, Lonza, Belgium), 2mM L-glutamine
(Sigma-Aldrich Company LTD, Saint Louis, MO, United States),
100 U/mL penicillin (Cepa S.L, Madrid, Spain), and 100µg/mL
streptomycin (Laboratorios Normon S.A, Madrid, Spain) in
Abbreviations: 7AAD, 7-Amino-actinomycin D; BMDC, bone marrow derived
dendritic; CD, cluster of differentiation; CFA, complete Freund’s adjuvant; CNS,
central nervous system; DC, dendritic cells; diffEP, DC trated with EP during
differentiation/propagation; EAE, experimental autoimmune encephalomyelitis;
EP, ethyl pyruvate; FCS, fetal calf serum; GM-CSF, granulocyte-macrophage
colony-stimulating factor; HLA, human leukocyte antigen; iDC, immature DC;
IFN, interferon; IL, interleukin; LPS, lipopolysaccharide; matEP, DC treated with
EP during maturation; mDC, mature DC; PBMC, peripheral blood mononuclear
cells; PBS, phosphate buffer saline; SD, standard deviation; Th, helper T cells; TNF,
tumor necrosis factor; tolDC, tolerogenic DC; Treg, regulatory T cells.
the presence of granulocyte-macrophage colony-stimulating
factor (GM-CSF: 1,000 U/ml; Peprotech, Freiburg, Germany)
and interleukin 4 (IL-4: 1,000 U/ml; Peprotech). Cells were
replenished on day 4 with fresh medium and cytokines. To
induce mature DC (mDC), DC were treated with a cocktail of
TNF (1,000 U/ mL), IL-1β (10 ng/mL) (both from Peprotech);
and PGE2 (1µM) (Pfizer, New York, NY, United States) on
day 4. Treatment with Vitamin D3 (vitDC, 1 nM, Calcijex, Kern
Pharma, Terrassa, Spain) was performed on days 0 and 4, while
treatment with EP (EPDC) was performed on days 2 and 4.
These cells were also stimulated as mature DCs at day 4 with the
cytokine cocktail. Immature DC (iDC) were not treated with the
maturation cocktail on day 4. On day 6, DC were harvested and
washed extensively twice, before phenotype was determined and
functional assays were performed.
Bone Marrow-Derived Murine DC
Murine DC were obtained from progenitor bone marrow cells
that were flushed from femur of NOD and C57BL/6 mice
(experiments were approved by the local ethics committee
of the Institute for Biological Research “Sinisa Stankovic,” in
accordance with Directive 2010/63/EU, N
◦
02-09/16). These
cells were cultured in RPMI 1640 (Biological Industries,
Kibbutz Beit-Haemek, Israel) supplemented with 10% FCS (PAA
Laboratories), 2mMglutamine and 1mM sodium pyruvate (both
from Sigma-Aldrich) (1 × 106/mL/well in 24-well plate). Bone
marrow derived dendritic cells (BMDC) were cultivated for
8 days in the presence of 20 ng/mL of GM-CSF (Peprotech
or Novus, Littleton, CO), with 100 ng/mL lipopolysaccharide
(LPS, Sigma-Aldrich) added for the last 24 h of cultivation for
maturation. Treatment with EP was performed on days 3 and 6
(diffEP) or simultaneously with LPS (matEP). Number of viable
cells was determined by trypan blue exclusion test on a LUNA-
IITM Automated Cell Counter from Logos Biosystems (Gyeonggi-
do, South Korea).
In vivo DC Application
Experiments were approved by the local ethics committee
(Institute for Biological Research “Sinisa Stankovic,” in
accordance with Directive 2010/63/EU, N
◦
03-01/17). Murine
DC were prepared as described above. mDC or EPDC were
injected subcutaneously into the hind paw of female 2–3 months
old C57BL/6 mice (1 × 106/80 µl/mouse). Complete Freund’s
adjuvant (CFA) was made from incomplete Freund’s adjuvant
(Difco, Detroit, MI) supplemented with M. tuberculosis (to 5
mg/ml, Difco). Each mouse was injected subcutaneously in
the hind paw with 50 µl of emulsion made from CFA mixed
with equal volume of phosphate buffer saline on the following
day. Popliteal lymph nodes were isolated from the mice 3 days
later and subjected to collagenase V (Sigma-Aldrich) digestion.
Lymph nodes were gently minced with scissors and incubated
with 1 mg/mL of Collagenase V solution in RPMI 1640 at 37◦C
with gentle shaking for 20min. Subsequently, the digestion was
stopped with FCS and the cells were pelleted by centrifugation.
Number of viable cells was determined by trypan blue exclusion
test on a LUNA-IITM Automated Cell Counter. For cell tracking,
DC were stained with CFSE (2µM, Invitrogen, Carlsbad, CA,
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United States) prior to injection. Determination of CFSE+ cells
among popliteal lymph node cells was performed on a CyFlow
Space flow cytometer (Partec, Munster, Germany).
CD4+ T Cell Isolation
CD4+ T cells were purified from cervical lymph nodes obtained
from BALB/c mice. For purification of CD4+ T cells from the
lymph nodes, a biotin-conjugated antibody specific for CD4
(Invitrogen) and IMagSAv Particles Plus (BD Biosciences, San
Diego, CA) were used in accordance with the manufacturers’
instructions. CD4+ T cells were stained with CFSE (2µM) prior
to cultivation with DC.
Allostimulatory Assays
Human DC were co-cultured with allogeneic human PBMC
(105 cells/ well) in 96-well round-bottom plates. PBMC
were co-cultured for 4 days (96 h) with MDDCs at a 1:20
ratio (DC: PBMC). Cell proliferation was determined by
incorporation of 1 µCi [3H]-thymidine (PerkinElmer, Waltham,
MA, United States) for 18 h on each well. Murine DC obtained
from C57BL/6 mice were co-cultured with CFSE-labeled CD4+
T cells obtained from BALB/c mice (105 cells/well) in 96-well
round-bottom plates. CD4+ T cells were co-cultured for 5 days
(120 h) with MDDCs at a 1:20 ratio (DC: CD4+ T cells). Cell
proliferation was determined by the sequential loss of CFSE
fluorescence, as detected by flow cytometry.
Immunostaining and Flow Cytometry
Human DC were washed, re-suspended in 50 µl of PBS and
incubated with mAbs for 20min protected from light at room
temperature (RT). After washing, acquisition was performed
on a FACSCanto II flow cytometer using FACSDiva software
(BD Biosciences, CA, United States). Subsequent analyses were
done using FlowJo software (Tree Star, Inc., OR, United States).
Samples were gated using forward (FSC) and side (SSC) scatter
to exclude dead cells and debris. The following human mAbs
were used: FITC-labeled mAbs: CD86 (BD Biosciences); PE-
labeled mAbs: CD14 (ImmunoTools GmbH, Germany), CD40
(BD Biosciences); PE-Cyanine dye 7-labeled mAb: CD14 and
CD11c (BD Biosciences); Allophycocyanin (APC)-labeled mAbs:
CD83, APC-H7-labeled mAb: HLA-DR (BD Biosciences).
Murine cells were washed, re-suspended in 100 µL of PBS
supplemented with 2% ofmouse serum and incubated withmAbs
for 30min at 4◦C. After washing, acquisition was performed
with a CyFlow Space flow cytometer. Samples were gated using
forward (FSC) and side (SSC) scatter to exclude dead cells
and debris, as well as using FSC and FSC-W to exclude cell
doublets. The following murine mAbs were used: PE-Cyanine5
labeled CD11c and CD86 (eBioscience), FITC-labeled CD40
(eBioscience).
Prior to intracellular cytokine staining, cells were stimulated
with eBioscienceTM Cell Stimulation Cocktail (plus protein
transport inhibitors), containing phorbol myristate acetate,
ionomycin and brefeldin A and monensin for 4 h, stained
with anti-CD4 PerCP-Cy5.5 antibody (eBioscience), fixed and
permeabilized with eBioscienceTM Intracellular Fixation and
Permeabilization Buffer Set and then stained for the intracellular
cytokines with the following antibodies: anti-mouse antibodies
against IL-17 or IFN-γ or IL-10 coupled with FITC or PE (all
from eBioscience). After washing, acquisition was performed
with a CyFlow Space flow cytometer. Samples were gated using
forward (FSC) and side (SSC) scatter to exclude dead cells and
debris, as well as using FSC and FSC-W to exclude cell doublets.
Isotype-matched controls were included in all experiments
(eBioscience).
ELISA
Cell culture supernatants were obtained and centrifuged to spin
down the cells. Cell-free supernatants were used in sandwich
ELISAs as instructed by the producers of the antibody pairs used.
Samples were analyzed in duplicates for murine TNF, murine IL-
6 (R&D Systems), murine IL-1β, murine IL-12 (eBiosciences),
murine IL-17 (eBioscience), human IFN-γ and human IL-10
(R&D Systems). Lower limit of detection was 30 pg/ml, whereas
upper limit of detection was 10 ng/ml for all of the ELISA tests
performed. Samples that showed values over the upper limit
of detection were adequately diluted for the measurement. The
results were calculated using standard curvesmade on the basis of
known concentrations of the appropriate recombinant cytokines.
Statistics
One-way ANOVA followed by Tukey’s multiple comparison
test or Student’s t-test (two-tailed) were used as appropriate
for statistical analysis. A p < 0.05 was considered statistically
significant.
RESULTS
EP Exerts Tolerogenic Effects on Mouse
BMDC
In order to determine if EP has tolerizing effects on NOD mice
BMDC in the course of their maturation, the agent was applied
during the last 24 h of their cultivation, simultaneously with
the maturing agent, i.e., LPS. Alternatively, to assess EP effect
on differentiation/propagation of DC from their bone marrow
precursors, the agent was applied to BMDC cultures on days
3 and 6 of their cultivation. EP applied during the maturation
had minimal effects on BMDC viability (Figure 1A), while no
effects on the cell viability were observed with the alternative
application of the agent (Figure 1B).While EP applied during the
differentiation reduced IL-1β production in BMDC, EP applied
duringmaturation had the opposite effect (Figure 1C). Both ways
of EP application led to the reduction of generation of IL-6, IL-
12, and TNF in BMDC (Figures 1D–F). Also, CD11c expression
was not affected, while both CD86 and CD40 expression were
decreased in EP-treated BMDC, irrespectively of the way of its
application (Figures 1G–J).
EP-Treated Mouse BMDC Are Inefficient
Allogeneic Stimulators in vitro
To test if the tolerogenic effects of EP can also be observed
in C57BL/6 BMDC, the same application protocols were used
as with NOD mice BMDC. EP did not affect cell viability and
CD11c expression, while it reduced generation of the examined
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FIGURE 1 | Effects of EP on NOD mice DC. BMDC were obtained from NOD
mice. They were treated with EP for 24 h simultaneously with LPS (A and
“maturation”) or at days 3 and 6 of the propagation (B and “differentiation”).
3.1mM EP was used in (C–I). Viability (A,B) was determined by trypan blue
exclusion assay. Cytokines were determined in cell culture supernatants by
ELISA (C–F). Proportion of cells expressing the listed antigens was determined
by cytofluorimetry (G–J). Data are presented as mean + SD from at least three
independent experiments. Data in (J) are representative plots. *p < 0.05, EP
vs. 0, one way ANOVA followed by Tukey’s multiple comparisons test (A,B),
two-tailed t-test (C–I).
pro-inflammatory cytokines and expression of CD40 and CD86,
irrespectively of the way of its application (Figures 2A–J). To
examine if these effects of EP affected BMDC ability to activate
T cells, EP-treated BMDC were co-cultured with allogeneic
CD4+ T cells from BALB/c mice. Proliferation of CD4+
T cells (Figures 3A,B) and their capacity to produce IL-17
(Figure 3C) were reduced in co-cultures with EP-treated BMDC
in comparison to those with the untreated BMDC.
EP Exerts Tolerogenic Effects on Human
MDDC
EP was added to MDDC cultures in the process of their
differentiation/propagation (EPDC) (Figure 4A). No effect of
EP on cell viability was observed on human MDDC that
were obtained from healthy subjects (Figure 4B) or individuals
suffering from multiple sclerosis (Figure 4C). EP-treated DC
were compared to vitamin D-treated DC (vitDC), non-treated
mature DC (mDC) and immature DC (iDC) in the following
experiments. There was no difference in the cell viability
among the examined DC populations (Figures 4D,E). Also,
no difference was observed in the level of CD11c expression
(Figures 4F–H). However, both vitDC and EPDC reduced
expression of HLA-DR, CD86, and CD83 in comparison
to mDC, both in healthy and multiple sclerosis individuals
(Figures 4F–H).
EP-Treated Human MDDC Are Inefficient
Allogeneic Stimulators in vitro
Tolerogenic properties of EPDC were examined in allogeneic co-
culture with PBMC. EPDC inhibited allogeneic cell proliferation
in comparison to mDC to the similar extent as vitDC
(Figures 5A,B). Effects of EPDC obtained with the highest
EP dose applied (12.5mM) were superior to those of vitDC
(Figures 5A,B). There was no difference in the inhibitory
activity of EPDC or vitDC obtained from healthy subjects or
individuals affected with multiple sclerosis. Levels of IFN-γ and
IL-10 in supernatants of the co-cultures were also determined.
IFN-γ levels were reduced in the samples obtained from co-
cultures performed with EPDC or vitDC in comparison to mDC
(Figures 5C,D), irrespectively if MDDC were obtained from
healthy individuals or the patients. However, IL-10 levels were
higher with EPDC or vitDC in comparison to mDC, only if
MDDC were obtained from healthy subjects (Figures 5C,D).
Allogeneic cell proliferation and the cytokine levels determined
with DC obtained from individual persons are presented, as well
(Figures 5E,F) in order to enable discrimination of responses
from different donors.
EP-Treated Mouse BMDC Show
Immunomodulatory Function in vivo
EPDC were applied in vivo to mice immunized with CFA as
depicted in Figure 6A. Their effects were compared to those of
mDC-treated mice, as well as to mice injected with vehicle only
(control). In order to track DC in vivo, the cells were labeled
with CFSE. CFSE-labeled EPDC and mDC were detectable in
popliteal lymph nodes 4 days after the injection (Figure 6B).
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FIGURE 2 | Effects of EP on C57BL/6 mice DC. BMDC were obtained from C57BL/6 mice. They were treated with EP (3.1mM) for 24 h simultaneously with LPS
(“matEP”) or at days 3 and 6 of the propagation (“difEP”) or they were untreated with EP (mDC), as schematized (A). Viability (B) was determined by trypan blue
exclusion assay. Cytokines were determined in cell culture supernatants by ELISA (C–F). Proportion of cells expressing the listed antigens was determined by
cytofluorimetry (G–J). Data are presented as mean + SD from at least three independent experiments. Data in (J) are representative plots. *p < 0.05, EP vs. mDC,
one way ANOVA followed by Tukey’s multiple comparisons test.
Popliteal lymph node cells were isolated for phenotypic analyses,
at the same time. There were no differences in cellularity and
proportion of CD4+ cells of popliteal lymph nodes isolated
from vehicle-, mDC-, and EPDC-treated mice (Figures 6C,D).
However, there were more IL-10+CD4+ cells in EPDC-treated
than in control mice (Figure 6E) and less IFN-γ+CD4+ cells
in EPDC-treated than in mDC-treated mice popliteal lymph
nodes (Figure 6F). Both, IL-10+CD4+ cells and IFN-γ+CD4+
cells were also more numerous in mDC-treated than in control
mice popliteal lymph nodes (Figures 6E,F). There were no
differences in proportion of IL-17+CD4+ cells among the groups
(Figure 6G). Importantly, ratio of IL-10+CD4+ cells to IFN-
γ+CD4+ cells, as well as to IL-17+CD4+ cells was higher in
popliteal lymph nodes of EPDC-treated mice in comparison to
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FIGURE 3 | Effects of murine EP-treated DC on allogeneic reactivity. BMDC were obtained from C57BL/6 mice. Their maturation was induced by LPS in the absence
(mDC) or presence of 3.1mM EP (diffEP). They were co-cultured with CD4+ T cells purified from BALB/C mice lymph nodes. Cell proliferation was determined by
CFSE assay (A,B). IL-17 levels were determined in cell culture supernatants by ELISA (C). Data are presented as mean + SD from at least three independent
experiments. Data in (B) are representative plots. *p < 0.05, diffEP vs. mDC, one way ANOVA followed by Tukey’s multiple comparisons test.
controls (Figures 6H,I). Moreover, ratio of IL-10+CD4+ cells
to IFN-γ+CD4+ cells was higher in popliteal lymph nodes of
EPDC-treated mice in comparison to mDC-treated mice.
DISCUSSION
Ethyl pyruvate modulates expression of antigen presentation-
related molecules on DC. It also reduces release of pro-
inflammatory cytokines from these cells. Moreover, it makes
DC inefficient in T cell activation. Importantly, the effects
are observed when EP is applied to DC during their
differentiation/propagation from precursor cells, as well as when
it is applied simultaneously with the maturation stimulus. EP-
treated DC modulate immune response initiated by CFA in vivo.
Thus, EP efficiently modulates immune activity of DC.
Our experiments on mice were performed with two mice
strains, i.e., NOD and C57BL/6 mice. The reason to use both
mice strains are our plans to expand the research to in vivo
systems, where EAE and type 1 diabetes in mice will be analyzed.
Both mouse strains are susceptible to EAE (12) induction, NOD
mice develop diabetes spontaneously (13), while C57BL/6 mice
are susceptible to multiple low dose streptozotocin-induced
diabetes (14). Also, in this way we were able to exclude strain-
specific effects of EP. The absence of genetic predisposition
toward susceptibility of DC to EP were even more convincingly
shown with human cells. There, the tolerizing effects of EP on
DC were observed with the cells obtained from more than 10
different individuals. What is more, the effects were consistent
with the cells obtained from healthy individuals, as well as with
those obtained from individuals affected by multiple sclerosis.
This implies that EP-treated DC are good candidates for a
tolerogenic cell-based therapy. Along this conclusion, EP-treated
DC were comparable to vitamin D3-treated DC, regarding their
immunomodulating properties. The highest dose of EP applied
in our study (12.5mM) was even superior to standard vitamin
D3 dose used (1 nM) when T cell proliferation was determined.
Having in mind that vitamin D3-induced tolDC have been
investigated in details in vitro and in vivo in EAE and that they are
currently tested in clinical trials in multiple sclerosis, the ability
of EP to act on DC in similar fashion is an additional impetus for
further studies toward clinical application of EP-treated DC as a
therapy for autoimmunity.
Interestingly, there was a difference in IL-10 production in
the co-cultures of tolDC with PBMC, depending on the source
of DC, i.e., whether the cells were obtained from healthy or
multiple sclerosis individuals. While IL-10 levels were increased
in the co-cultures of tolDC from healthy individuals, they were
not increased in the co-cultures of tolDC from multiple sclerosis
individuals. This discrepancy was observed irrespectively of
the tolerizing agent used (EP or vitamin D3). It is proposed
that IL-10 plays the crucial role in immunomodulatory activity
of tolDC, as it induces differentiation of regulatory T cells
(15). Thus, the observed phenomenon is worthy of further
investigation, as it could be potentially disadvantageous to
therapeutic potential of EP- and vitamin D3-induced tolDC.
Also, the possibility of inherent reduced capacity of DC and
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FIGURE 4 | Effects of EP on human DC. MDDC were propagated from peripheral blood monocytes and matured in the presence of TNF+IL-1β+PGE2 (mDC, vitDC,
tEPDC) or were left immature without the treatment (iDC) as depicted (A). MDDC were obtained from healthy subjects (B,D,F,H) or from individuals affected by
multiple sclerosis (C,E,G). EP was applied in various concentrations (B,C) or in concentration of 6.2mM (D–H, EPDC). Vitamin D3 (vitDC) was applied in
concentration of 1 nM. Viability (B–E) was determined by 7AAD test. Proportion of cells expressing the listed antigens was determined by cytofluorimetry (F–H). Data
are presented as mean + SD from at least five individuals. Data in H are representative plots. *p < 0.05 vs. mDC, two-tailed t-test.
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FIGURE 5 | Effects of human EP-treated DC on allogeneic reactivity. MDDC were obtained from healthy subjects (A,C,E) or from individuals affected by multiple
sclerosis (B,D,F). The cells matured in the presence of TNF+IL-1β+PGE2 (mDC, vitDC, EPDC) or were left immature without the treatment (iDC). EP was applied in
various concentrations (A,B) or in concentration of 3.1mM (C–F). Vitamin D3 (vitDC) was applied in concentration of 1 nM. MDDC were co-cultured with allogeneic
PBMC. Cell proliferation was determined by 3H incorporation test (A,B,E,F). Cytokines were determined in cell culture supernatants by ELISA (C–F). Data in (A,B) are
presented as mean ± SD from a number of individuals depicted as the open circles. Data in (C,D) are presented as mean + SD from four individuals. Data from four
individuals are presented in (E,F), where the same person has a unique symbol (circle, square, triangle, or trapezoid). *p < 0.05, vs. mDC in (C,D), one way ANOVA
followed by Tukey’s multiple comparisons test.
other immune cells of multiple sclerosis patients to produce
IL-10 warrants additional studies as it might be important
for understanding the predisposition of humans toward the
development of multiple sclerosis. Indeed, reduction in the
proportion of IL-10-producing PBMC in multiple sclerosis
patients (16), as well as of IL-10 mRNA expression in these cells
(17, 18) were previously reported. However, multiple sclerosis
patients and healthy subjects from whom blood samples were
obtained were not adjusted to age, sex, and other relevant
parameters that could bias our observation on the differential IL-
10 response. Also, higher number of samples would be needed
for the determination of the statistical correlation between the
levels of cell proliferation and IL-10 or IFN-γ production within
groups of healthy subjects and multiple sclerosis patients, as well
as between these two groups. Therefore, further studies enrolling
higher number of individual samples for the exploration of the
effects of EP on human DC, including their ability to generate
IL-10 are needed. However, the fact that the samples were not
adjusted between multiple sclerosis and healthy subjects did not
jeopardize the general conclusion about tolerizing potency of EP-
treated DC, i.e., EP-treated DC had the same, if not stronger
tolerizing effects in comparison to classical tolDC induced by
vitamin D3, irrespectively if they were obtained from the healthy
subjects or the patients.
EP-treated DC applied to mice immunized with CFA shifted
draining lymph node cytokine milieu from IFN-γ/IL-17- toward
IL-10-dominated. EP-treated DC injected at the site of injection
efficiently migrated toward regional lymph nodes and imposed
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FIGURE 6 | Effects of murine EP-treated DC on CFA-induced immune response in vivo. Schematic representation of C57BL/6 mice treatment (A). Number of CFSE+
cells (B), total number of cells (C), and proportion of CD4+ cells (D) was determined in popliteal lymph nodes by flow cytometry (B,D) or cell counting (C). Proportion
of IL-10+ (E), IFN-γ+ (F), and IL-17+ (G) cells among CD4+ cells was determined by flow cytometry. Ratio of the cytokines expressing CD4+ cells is presented, as
well (H,I). Data from three experiments are presented as mean ± SD from a number of mice depicted as the circles, squares, or triangles. *p < 0.05, one way ANOVA
followed by Tukey’s multiple comparisons test.
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the immunomodulatory effect. The observed modulation of the
cytokine-generating T cell balance is particularly fascinating,
as it was observed in strong inflammatory setting induced by
CFA. Thus, immunomodulatory effects of EP-treated DC are
rather potent and the one can expect that the effects would
persist in antigen-specific setting, as well. Of course, in the
context of a certain autoimmune disease it would be important
to determine if EP-treated DC loaded with relevant antigens
would acquire specificity of immunomodulatory actions. Thus,
our results imply that EP-treated DC dampen initiation and
propagation of an immune response in lymphoid organs, an
effect that should be useful in restricting the immunopathology of
autoimmune and chronic inflammatory diseases. This possibility
will be explored in details in specific models of autoimmunity,
such as type 1 diabetes in NOD mice and EAE in our future
studies.
We have previously shown that EP exerts immunomodulatory
properties in animal models of multiple sclerosis and type
1 diabetes (6, 19). Here we extend our observation and we
introduce a novel biological effect of EP, i.e., its ability to induce
tolerogenic DC in vitro. Moreover, EP-treated DC are efficient
in modulating an immune response in vivo. EP applied to DC
during the process of differentiation inhibits their response to
the maturation stimulus, both regarding expression of antigen-
presenting and co-stimulatory molecules and production of
relevant pro-inflammatory cytokines. Also, EP-treated DC are
impotent allogeneic stimulators of CD4+ T cells. Importantly,
the effects are observed in human cells and not only murine
cells. Further studies are needed for determination of molecular
mechanisms behind the effects of EP. Also, in vivo studies on
animal models of autoimmunity are necessary. These studies
should help to elucidate if EP-treated DC are good candidates
for clinical trials of multiple sclerosis and other autoimmune
disorders.
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